Dr. Craig W. Lindsley is the Director of Medicinal Chemistry for the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) and the Center co-Director with Jeff Conn at Vanderbilt University focused on the development of allosteric modulators of GPCRs for the treatment of schizophrenia, Parkinson’s disease, Alzheimer’s disease, fragile X syndrome and depression.
After brief stints at Parke-Davis and Eli Lilly, Dr. Lindsley accepted a position at Merck & Co. Inc. (West Point) and developed a streamlined approach for lead optimization and provided critical proof-of-concept compounds that validated the mechanism of allosteric modulation. In late 2006, Dr. Lindsley moved to Vanderbilt as an Associate Professor of Pharmacology and Chemistry. In addition to serving as the Director of Medicinal Chemistry for the VCNDD, Dr. Lindsley also serves as Director of the Vanderbilt MLSCN Chemistry Center and co-Director of the Vanderbilt Institute of Chemical Biology (VICB) Synthesis Core. He is also on the scientific advisory board to the National Chemical Genomics Research Center and a world-wide Medicinal Chemistry consultant for both Amgen and the Michael J Fox Foundation.
Dr. Lindsley has served as a reviewer for a large number of journals and currently serves on the Editorial Board of the Journal of Combinatorial Chemistry and as Editor-in Chief of ACS Chemical Neuroscience.